Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shehuang is a Traditional Chinese Medicine (TCM) topical formulation developed by Chengdu Huasen Pharmaceutical High-Tech Co., Ltd. for the treatment of chronic eczema. Formulated as a cream, it is designed to leverage the anti-inflammatory, antipruritic, and antimicrobial properties of traditional ingredients, likely including artificial musk and sulfur. The drug has been evaluated in a Phase II, randomized, double-blind, placebo-controlled clinical trial (CTR20132696) in China to assess its safety and efficacy in patients with chronic eczema. As a botanical-based therapy, it aims to provide a therapeutic alternative for managing the persistent inflammation and itching associated with chronic dermatological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shehuang (Huasen Pharmaceutical).